Literature DB >> 19687233

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

G L Drusano1, O O Okusanya, A O Okusanya, B van Scoy, D L Brown, C Fregeau, R Kulawy, M Kinzig, F Sörgel, H S Heine, A Louie.   

Abstract

Bacillus anthracis is complex because of its spore form. The spore is invulnerable to antibiotic action. It also has an impact on the emergence of resistance. We employed the hollow-fiber infection model to study the impacts of different doses and schedules of moxifloxacin on the total-organism population, the spore population, and the subpopulations of vegetative- and spore-phase organisms that were resistant to moxifloxacin. We then generated a mathematical model of the impact of moxifloxacin, administered by continuous infusion or once daily, on vegetative- and spore-phase organisms. The ratio of the rate constant for vegetative-phase cells going to spore phase (K(vs)) to the rate constant for spore-phase cells going to vegetative phase (K(sv)) determines the rate of organism clearance. The continuous-infusion drug profile is more easily sensed as a threat; the K(vs)/K(sv) ratio increases at lower drug exposures (possibly related to quorum sensing). This movement to spore phase protects the organism but makes the emergence of resistance less likely. Suppression of resistance requires a higher level of drug exposure with once-daily administration than with a continuous infusion, a difference that is related to vegetative-to-spore (and back) transitioning. Spore biology has a major impact on drug therapy and resistance suppression. These findings explain why all drugs of different classes have approximately the same rate of organism clearance for Bacillus anthracis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687233      PMCID: PMC2772353          DOI: 10.1128/AAC.00802-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Authors:  Henry S Heine; Arnold Louie; Fritz Sorgel; Jennifer Bassett; Lynda Miller; Lawrence J Sullivan; Martina Kinzig-Schippers; George L Drusano
Journal:  J Infect Dis       Date:  2007-07-19       Impact factor: 5.226

2.  Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Authors:  Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Authors:  J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Inhibition of Bacillus anthracis growth and virulence-gene expression by inhibitors of quorum-sensing.

Authors:  Marcus B Jones; Rachana Jani; Dacheng Ren; Thomas K Wood; Martin J Blaser
Journal:  J Infect Dis       Date:  2005-04-29       Impact factor: 5.226

5.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

6.  Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Authors:  Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

  6 in total
  6 in total

Review 1.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

2.  Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Authors:  Arnold Louie; Brian D Vanscoy; Henry S Heine; Weiguo Liu; Terry Abshire; Kari Holman; Robert Kulawy; David L Brown; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Authors:  Arnold Louie; Brian D VanScoy; David L Brown; Robert W Kulawy; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.

Authors:  G L Drusano; Stephanie Rogers; David Brown; C A Peloquin; Michael Neely; Walter Yamada; Sarah Kim; Mohammed Almoslem; Stephan Schmidt; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

6.  Pressure and Temperature Combined With Microbial Supernatant Effectively Inactivate Bacillus subtilis Spores.

Authors:  Jingyu Li; Yaxin Sun; Fang Chen; Xiaosong Hu; Li Dong
Journal:  Front Microbiol       Date:  2021-05-18       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.